"Palivizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody and ANTIVIRAL AGENT that is used to prevent RESPIRATORY SYNCYTIAL VIRUS INFECTIONS in high risk pediatric patients.
| Descriptor ID |
D000069455
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.860 D12.776.124.790.651.114.224.060.860 D12.776.377.715.548.114.224.200.860
|
| Concept/Terms |
MEDI 493- MEDI 493
- Monoclonal Antibody MEDI-493
- Monoclonal Antibody MEDI 493
- Monoclonal Antibody MEDI493
- MEDI-493
- MEDI493
|
Below are MeSH descriptors whose meaning is more general than "Palivizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Palivizumab [D12.776.124.486.485.114.224.060.860]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Palivizumab [D12.776.124.790.651.114.224.060.860]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Palivizumab [D12.776.377.715.548.114.224.200.860]
Below are MeSH descriptors whose meaning is more specific than "Palivizumab".
This graph shows the total number of publications written about "Palivizumab" by people in this website by year, and whether "Palivizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 2 | 2 | 4 |
| 2025 | 1 | 1 | 2 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Palivizumab" by people in Profiles.
-
Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial. JAMA Pediatr. 2026 Sep 01; 180(9):951-960.
-
Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemp Clin Trials. 2025 10; 157:107995.
-
Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2023 07 01; 152(1).
-
Improvement in Palivizumab Administration Prior to Discharge for Hospitalized Infants with Hemodynamically Significant Congenital Heart Disease: A Quality Improvement Initiative. Pediatr Cardiol. 2024 Oct; 45(7):1415-1423.
-
Palivizumab Prophylaxis for Healthy Preterm Infants: More Data Supporting American Academy of Pediatrics Guidelines. Pediatrics. 2016 08; 138(2).
-
Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol. 2014 Aug; 36(6):e376-81.
-
Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model. Pharmacotherapy. 2014 Mar; 34(3):251-9.
-
The value of budget impact analyses in evaluating targeted therapies-The case of RSV prophylaxis for preterm infants. Value Health. 2011 Jan; 14(1):201-2.